Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927922 | 0.92 | MAP3K5 (0.83) | MAP3K5AKT1 | |
| SCHEMBL19927925 | 0.92 | MAP3K5 (0.82) | MAP3K5AKT1 | |
| SCHEMBL19927923 | 0.92 | MAP3K5 (0.83) | MAP3K5AKT1 | |
| SCHEMBL15811894 | 0.90 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL15835592 | 0.89 | MAP3K5 (0.82) | MAP3K5AKT1 | |
| SCHEMBL19927939 | 0.89 | MAP3K5 (0.83) | MAP3K5AKT1 | |
| SCHEMBL19927932 | 0.89 | MAP3K5 (0.83) | MAP3K5AKT1 | |
| SCHEMBL19927936 | 0.89 | MAP3K5 (0.75) | MAP3K5AKT1 | |
| SCHEMBL19927934 | 0.89 | MAP3K5 (0.82) | MAP3K5AKT1 | |
| SCHEMBL19927929 | 0.89 | MAP3K5 (0.82) | MAP3K5AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051313-B2 | Apoptosis signal-regulating kinase inhibitors | GILDEAD SCIENCES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140179663-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179663-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, DAPK1 | MAP3K5 12/4885AKT1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.